Oncopeptides announces that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to Oncoeptides.
The patent (application JP 2015-539556) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent will expire in October 2033.
“We are pleased to have received this patent notice which was in line with our expectations and it represents an important milestone for Ygalo’s future potential commercial value in this key territory. Last year a similar patent was granted in Europe, which increases the protection of Ygalo beyond the composition of matter patent and orphan drug exclusivity periods” commented Jakob Lindberg, CEO Oncopeptides.